Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2024-03-04 00:00:00 ET · period of report 2024-02-29 · accession 0001415889-24-006322 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-03-04 | 2024-02-29 | OLMA | Harmon Cyrus | Dir | S - Sale | $12.41 | -25.0K | 846.3K | -3% | -$310.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-29 | S | D | 24,900 | $12.41 | 846,383 | D | — | — | (F2) The weighted average sale price for the transaction reported was $12.41, and the range of prices was between $11.94 and $12.86. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2024-02-29 | S | D | 100 | $13.00 | 846,283 | D | — | — | (F3) The weighted average sale price for the transaction reported was $13.00, and the range of prices was between $12.97 and $13.01. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |